Mercer Global Advisors Reduces $5M in Apogee Therapeutics, Inc. ($APGE)
Key Points
- Mercer Global Advisors changed its Apogee Therapeutics, Inc. ($APGE) stake by 6.7% last quarter, cutting to 831,428 shares worth $74.41 million.
- Wall Street's consensus rating on $APGE is Strong Buy and an average price target of $119.50.
- $APGE last traded around $89.50.
Mercer Global Advisors trimmed its position in Apogee Therapeutics, Inc. ($APGE) by 6.7% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 831,428 shares of Apogee Therapeutics, Inc. after selling 59,237 shares during the quarter. Mercer Global Advisors's holdings in Apogee Therapeutics, Inc. were worth $74.41 million as of its most recent filing.
Apogee Therapeutics, Inc. ($APGE) Stock
Apogee Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.